Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China.
Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ann Hematol. 2023 Jul;102(7):1879-1886. doi: 10.1007/s00277-023-05225-2. Epub 2023 Apr 19.
Primary mediastinal large B-cell lymphoma is a rare subtype of lymphoma. The contemporary incidence of primary mediastinal large B-cell lymphoma remains unknown, and a large population-based study has not been reported. It is essential to provide guidance for further strategies in reducing the disease burden via population-based preventive initiatives. This study aims to explore the epidemiology and effect of therapeutic advances on the survival of patients with primary mediastinal large B-cell lymphoma. This population-based study was conducted using the Surveillance, Epidemiology, and End Results Program (SEER), covering the period from 1975 to 2018. A total of 774 patients in the SEER 9 and 1654 patients in the SEER 18 were analyzed. The age-adjusted incidence rate of primary mediastinal large B-cell lymphoma increased from 0.05/1,000,000 in 1975 to 2.38/1,000,000 in 2018. A significant positive linear increase in the incidence trend was found in primary mediastinal large B-cell lymphoma, with an annual percent change of 8.47% (95% confidence interval 7.7-9.2%, P < 0.001, z test). The survival in primary mediastinal large B-cell lymphoma was significantly superior to nodal diffuse large B-cell lymphoma. The incidence of PMBCL increases over the year. The survival of patients with primary mediastinal large B-cell lymphoma has improved over time.
原发性纵隔大 B 细胞淋巴瘤是一种罕见的淋巴瘤亚型。原发性纵隔大 B 细胞淋巴瘤的当代发病率尚不清楚，也没有大型基于人群的研究报告。通过基于人群的预防措施为进一步降低疾病负担提供指导至关重要。本研究旨在探讨原发性纵隔大 B 细胞淋巴瘤的流行病学和治疗进展对患者生存的影响。这项基于人群的研究使用了监测、流行病学和最终结果计划（SEER），涵盖了 1975 年至 2018 年的时间段。分析了 SEER 9 中的 774 例患者和 SEER 18 中的 1654 例患者。原发性纵隔大 B 细胞淋巴瘤的年龄调整发病率从 1975 年的 0.05/100 万增加到 2018 年的 2.38/100 万。原发性纵隔大 B 细胞淋巴瘤的发病趋势呈显著正线性增加，年变化百分比为 8.47%（95%置信区间为 7.7-9.2%，P<0.001，Z 检验）。原发性纵隔大 B 细胞淋巴瘤的生存情况明显优于结内弥漫性大 B 细胞淋巴瘤。PMBCL 的发病率逐年上升。原发性纵隔大 B 细胞淋巴瘤患者的生存情况随着时间的推移有所改善。
